Achondroplasia
Achondroplasia is a genetic disorder that results in abnormal bone growth, leading to short stature and characteristic features such as a larger head and shorter limbs. It is the most common form of dwarfism.
Achondroplasia: Infigratinib for Children
We are investigating a new medication, infigratinib, for children aged 3 to under 18 with achondroplasia. The study aims to see if it helps improve growth and body proportions while ensuring safety.
>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOralOrthopedics and TraumatologyPediatrics
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 3 and 17 years old?
- Do you have a diagnosis of achondroplasia (ACH) confirmed by genetic testing?
- Are you currently taking any medications that could affect your calcium or phosphorus levels?
- Have you had any surgeries to lengthen your limbs or are you planning to have one?
- Are you able to swallow oral medication?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Infigratinib
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Hopital Des Enfants
Pédiatrie - Endocrinologie, génétique et gynécologie médicale
Blagnac, France
Hospices Civils De Lyon
Service génétique clinique
Bron, France
Hopital Necker Enfants Malades
Service de médecine génomique des maladies rares
Montrouge, France
Sponsor: QED Therapeutics Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.